Conditions: Hepatic Insufficiency
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 35
Healthy volunteers: yes

Brief summary:
The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when given to participants with mild, moderate, or severe liver impairment compared to healthy participants. In addition, the tolerability of the study drug will be evaluated.

This study will last approximately 3 weeks for each participant, including check-in and follow-up.

Detailed description:

Arms:
arm 1: Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function. arm 2: Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment. arm 3: Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment. arm 4: Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.

Interventions: intervention 1: Abemaciclib
Intervention descriptions: intervention 1: Administered Orally

Protocol document: